|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM28488359X |
003 |
DE-627 |
005 |
20231225044140.0 |
007 |
cr uuu---uuuuu |
008 |
231225s2018 xx |||||o 00| ||eng c |
024 |
7 |
|
|a 10.1016/j.clim.2018.05.006
|2 doi
|
028 |
5 |
2 |
|a pubmed24n0949.xml
|
035 |
|
|
|a (DE-627)NLM28488359X
|
035 |
|
|
|a (NLM)29842945
|
035 |
|
|
|a (PII)S1521-6616(18)30065-2
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Lord, James D
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype
|
264 |
|
1 |
|c 2018
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a Date Completed 27.08.2019
|
500 |
|
|
|a Date Revised 27.08.2019
|
500 |
|
|
|a published: Print-Electronic
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.
|
520 |
|
|
|a Integrin alpha4/beta7 on circulating lymphocytes identifies them as gut-tropic, and can be targeted by the humanized antibody vedolizumab to treat inflammatory bowel disease (IBD). We found lymphocytes expressing alpha4/beta7 were significantly more responsive to the pro-inflammatory cytokines IL-6, IL-7, and IL-21, and less responsive to the regulatory T cell (Treg)-supporting cytokine IL-2. Alpha4/beta7 was expressed by a smaller percent of FOXP3 + Helios+ thymically-derived Tregs (tTregs) than FOXP3 + Helios- peripherally-derived Tregs (pTregs) or FOXP3- effector T cells. Integrin alpha4/beta7+ CD4 T cells were also rare among cells expressing the Th2 marker CRTh2, but enriched in cells bearing the circulating T follicular helper cell marker CXCR5. Thus the effect of this anti-integrin therapy on the mucosal immune system may be more qualitative than quantitative, and selectively replace pro-inflammatory effector cells with Tregs and Th2 cells to facilitate immune tolerance in the mucosa without globally depleting lymphocytes from the intestinal mucosa
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
650 |
|
4 |
|a Crohn's disease
|
650 |
|
4 |
|a FOXP3
|
650 |
|
4 |
|a Helios
|
650 |
|
4 |
|a IL-2, IL-6, IL-7, IL-21
|
650 |
|
4 |
|a Integrin
|
650 |
|
4 |
|a Stat
|
650 |
|
4 |
|a Th1
|
650 |
|
4 |
|a Th2
|
650 |
|
4 |
|a Treg
|
650 |
|
4 |
|a Vedolizumab
|
650 |
|
4 |
|a cT(FH)
|
650 |
|
7 |
|a Antibodies, Monoclonal, Humanized
|2 NLM
|
650 |
|
7 |
|a CXCR5 protein, human
|2 NLM
|
650 |
|
7 |
|a Cytokines
|2 NLM
|
650 |
|
7 |
|a FOXP3 protein, human
|2 NLM
|
650 |
|
7 |
|a Forkhead Transcription Factors
|2 NLM
|
650 |
|
7 |
|a Gastrointestinal Agents
|2 NLM
|
650 |
|
7 |
|a IKZF2 protein, human
|2 NLM
|
650 |
|
7 |
|a Inflammation Mediators
|2 NLM
|
650 |
|
7 |
|a Integrins
|2 NLM
|
650 |
|
7 |
|a Receptors, CXCR5
|2 NLM
|
650 |
|
7 |
|a integrin alpha4beta7
|2 NLM
|
650 |
|
7 |
|a Ikaros Transcription Factor
|2 NLM
|
650 |
|
7 |
|a 148971-36-2
|2 NLM
|
650 |
|
7 |
|a vedolizumab
|2 NLM
|
650 |
|
7 |
|a 9RV78Q2002
|2 NLM
|
700 |
1 |
|
|a Long, S Alice
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Shows, Donna M
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Thorpe, Jerill
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Schwedhelm, Katherine
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Chen, Janice
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Kita, Mariko
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Buckner, Jane H
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 193(2018) vom: 25. Aug., Seite 24-32
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:193
|g year:2018
|g day:25
|g month:08
|g pages:24-32
|
856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.05.006
|3 Volltext
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 193
|j 2018
|b 25
|c 08
|h 24-32
|